Mylan Institutional LLC
Mylan Institutional LLC, a prominent player in the pharmaceutical industry, is headquartered in Ireland (IE) and operates extensively across various global markets. Founded in 1961, the company has established itself as a leader in providing high-quality generic and specialty medications, particularly in the institutional healthcare sector. Mylan Institutional focuses on delivering a diverse range of injectable and non-injectable products, catering to hospitals and healthcare providers. Its commitment to quality and affordability sets it apart in a competitive landscape. Over the years, Mylan has achieved significant milestones, including strategic partnerships and a robust product portfolio that addresses critical healthcare needs. With a strong market position, Mylan Institutional is recognised for its innovative solutions and dedication to improving patient outcomes, making it a trusted name in the pharmaceutical field.
DitchCarbon Score
How does Mylan Institutional LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan Institutional LLC's score of 32 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mylan Institutional LLC's reported carbon emissions
Mylan Institutional LLC, headquartered in Ireland (IE), currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the company is likely to be engaged in industry-standard practices aimed at reducing environmental impact, as many pharmaceutical companies are increasingly focusing on sustainability and climate action. As the industry evolves, Mylan may adopt initiatives aligned with global climate goals, potentially including commitments to reduce greenhouse gas emissions across Scope 1, 2, and 3 categories. Stakeholders can expect that Mylan will continue to monitor and report on its environmental performance in the future, reflecting a growing trend towards transparency and accountability in corporate climate strategies.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mylan Institutional LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
